Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial

BACKGROUND: Currently there are no disease-modifying treatments for Parkinson’s disease dementia (PDD), a condition linked to aggregation of the protein α-synuclein in subcortical and cortical brain areas. One of the leading genetic risk factors for Parkinson's disease is being a carrier in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Silveira, C. R. A., MacKinley, J., Coleman, K., Li, Z., Finger, E., Bartha, R., Morrow, S. A., Wells, J., Borrie, M., Tirona, R. G., Rupar, C. A., Zou, G., Hegele, R. A., Mahuran, D., MacDonald, P., Jenkins, M. E., Jog, M., Pasternak, S. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368728/
https://www.ncbi.nlm.nih.gov/pubmed/30738426
http://dx.doi.org/10.1186/s12883-019-1252-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368728/
https://www.ncbi.nlm.nih.gov/pubmed/30738426
http://dx.doi.org/10.1186/s12883-019-1252-3

Ejemplares similares